Physician profile
Lotfi Hadad
NPI 1952362477
$1,247.56
in general payments reported to CMS, 2019-2025
27 companies · $39.53 in 2025
The $39.53 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $136 · 2021: $463 · 2022: $223 · 2023: $58.81 · 2024: $101 · 2025: $39.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $317.61 | 2021-2023 | Symtuza |
| Genentech USA, INC. | $145.27 | 2019-2024 | Ocrevus, Xolair, Ocrevus Zunovo |
| Dexcom, INC. | $137.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $80.97 | 2020-2022 | |
| Novo Nordisk INC | $58.94 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $55.95 | 2020-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $32.50 | 2019 | |
| Celgene Corporation | $32.49 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.59 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $25.99 | 2021 | |
| Pfizer INC. | $22.23 | 2025 | |
| Seagen INC. | $20.33 | 2019 | |
| Lundbeck LLC | $20.19 | 2024 | Vyepti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.96 | 2019 | |
| Genzyme Corporation | $19.57 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.49 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.20 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.51 | 2022 | |
| Amarin Pharma, INC. | $16.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.23 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.76 | 2019 | |
| Incyte Corporation | $13.49 | 2020 | |
| Theratechnologies INC. | $13.12 | 2020 | |
| Neos Therapeutics, LP | $13.12 | 2020 | |
| Emd Serono, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lotfi Hadad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.